Dosages; See below
Combinations; See below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Hemabate | Pfizer Global Pharmaceuticals | Laborex Kenya Eurapharma Ltd | 250mg | 10ml | Injection | per vial | KES 33,717.46 |
| Carboprost More info | |
|---|---|
| Mode Of Action | Stimulation of gravid uterus to produce myometrial contractions e.g. carboprast |
| Drug Indication | Aborting pregnancy 13th-20th wks of gestation and in the 2nd trimester due to various clinical causes; postpartum haemorrhage due to uterine atony unresponsive to conventional methods of management such oxytocin. |
| Precautions | History of asthma, hypo- or hypertension, cardiovascular, renal, or hepatic disease, anaemia, jaundice, diabetes, or epilepsy. Compromised (scarred) uteri |
| Contra-Indications | Acute PID; active cardiac, pulmonary, renal or hepatic disease; hypersensitivity to the active substance or to any of the excipients |
| Side Effects | Generally transient and reversible when therapy ends as they are mostly related to its contractile effect on smooth muscle. They include:vomiting; diarrhea; nausea; flushing or hot flashes; chills or shivering; coughing, headaches; endometritis; hiccough; dysmenorrhea-like pain; paresthesia; backache; muscular pain |
| Dosage | 250mcg IM and subsequent doses of 250mcg 1- 3 hours intervals depending on uterine response (not to exceed 12mg and continuous administration for more than 2 days) |
| Special Information | 15S)-15-methyl prostaglandin F2 tromethamine salt |
| Drug Category | DRUGS ACTING ON GENITO-URINARY SYSTEM |
| Drug Sub-Category | Drugs acting on uterus |